Abstract Limb-girdle muscular dystrophies (LGMD) are a highly heterogeneous group of genetic myopathies characterized by progressive proximal pelvic and/or shoulder girdle muscle weakness, with the onset ages ranging from early childhood to late adulthood. The identification of these dystrophies through genetic testing will not only inform longterm prognosis but will also assist in directing care more efficiently, including more frequent cardiorespiratory monitoring and prophylactic treatments. The aim of this study was to identify the responsible gene in a five-generation Chinese Han pedigree with autosomal recessive LGMD. Exome sequencing was conducted and a novel mutation c.107788T>C (p.W35930R) in the titin gene (TTN) was identified. The mutation co-segregated with the disorder in the family and was absent in normal controls. Our discovery broadens the mutation spectrum of the TTN gene associated with LGMD2J.
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Single nucleotide polymorphisms Limb-girdle muscular dystrophies (LGMD) are a highly heterogeneous group of genetic myopathies characterized predominantly by progressive proximal pelvic and/or shoulder girdle muscle weakness, with the onset ages ranging from early childhood to late adulthood [1, 2] . The disease prevalence varies from 0.07/100,000 to 0.43/100,000 based on the ethnic background [1] . Although most patients present with slowly progressive symmetrical weakness, the variable clinical pictures in patients with LGMD range from mild forms with nearly normal life span and motor function to severe forms with rapid progression or involvement of the heart or respiratory muscles [3] . Cardiac problems may occur first, overlap with or follow skeletal muscle weakness [4] . Distal muscle weakness and/or scapuloperoneal weakness may be affected in later stage or in severe forms [1, 5] . Serum creatine kinase (CK) levels vary widely among patients with LGMD, ranging from normal or mildly elevated in the majority of autosomal dominant LGMD to highly elevated as much as 10-100 times normal in some autosomal recessive LGMD [6] . CK levels are not specific in the diagnosis of LGMD, but they may be a useful approach for excluding metabolic or acquired myopathic diseases [7] . Electromyography (EMG) presents with short-duration, smallamplitude motor units with early recruitment in affected muscles, though EMG abnormalities may be subtle in the mild individuals [1] . Classic pathological features in LGMD include necrocytosis and regeneration of myocytes with different degrees of fibrosis and fatty infiltration [5] . The LGMD are divided into autosomal dominant LGMD1 and autosomal recessive LGMD2 based on the inheritance mode, with an appended letter behind which referring to the order of discovery for different chromosomal loci [8, 9] . The majority of, but not all, LGMD1 patients begin experiencing symptoms following their twenties. The vast majority of LGMD2 cases have teenage onset of progressive muscle weakness, though some patients exhibit mild weakness as late as 70 years old [4, 10, 11] . Comprehensive analysis of clinical, electrophysiological and physiological findings, imaging, and biochemical data, may be contributed to the clinical diagnosis of the LGMD. Thirty-one loci associated with LGMD have been mapped to date. Autosomal dominant LGMD include
LGMD1A-H and autosomal recessive LGMD include LGMD2A-W [12] , and many gene mutations were identified. The same mutation can present with different patterns of weakness in different patients with LGMD, or even within the same family. Conversely, a single LGMD phenotype can result from different gene mutations. However, the genetic testing techniques are the most efficient tools for identifying the diagnosis and the classification of LGMD. The genotypephenotype correlational analysis may be challenging due to the roles of background genes or environmental factors. The aim of this study was to identify the gene responsible for LGMD2 in a Chinese pedigree. A novel mutation c.107788T>C (p.W35930R) in the TTN gene was suggested to be the genetic cause of LGMD2J in this family.
Materials and Methods
Pedigree and Subjects
A five-generation consanguineous Chinese family with LGMD2 was enrolled in this study (Fig. 1) . All the available individuals were subjected to a thorough neurological examination by two or more experienced neurologists. All patients were clinically diagnosed at the Third Xiangya Hospital, Central South University, China. Individuals were considered to be affected if they demonstrated progressive proximal pelvic and/or shoulder girdle muscle weakness. Other information on age at onset, symptoms at onset, CK level, EMG, atrophic muscles, and ultrasonic cardiogram was obtained. Biopsy of right vastus lateralis was performed in patient V-3. Two hundred unrelated ethnically matched normal controls (male/female: 100/100, age 35.4±8.9 years) without diagnostic features of LGMD were recruited from the same region of Mainland China. The study complied with the Declaration of Helsinki Principles and was approved by the ethics committee of the Third Xiangya Hospital of Central South University in China. After written informed consent was obtained from all subjects, venous blood samples were obtained from three patients (V-1, V-3, and V-4) and three unaffected family members (IV-1, IV-2, and V-2) for isolation of genomic DNA. Genomic DNA was extracted according to standard phenol-chloroform extraction method [13] .
Exome Capture
To systematically search for disease-causing gene, exome sequencing in an affected individual (V-3, Fig. 1 ) from the LGMD2 family was performed using the Agilent's SureSelect Human All Exon V5 Kit on the Illumina HiSeq 2000 platform by Novogene Bioinformatics Technology Co., Ltd. 1.5 μg of genomic DNA of the proband (V-3) was used to construct the exome library. The genomic DNAwas sheared into 180-280 bp by sonication and hybridized for enrichment, following the manufacturer's protocol. The library enriched for target regions was sequenced on the Illumina HiSeq 2000 platform to get paired-end reads with read length of 100 bp.
Read Mapping and Variant Analysis
The human reference genome was obtained from the UCSC database (build 37.1, version hg19, http://genome.ucsc.edu/), and sequence alignment was performed using the BurrowsWheeler Alignment tool. High-quality alignment was required to guarantee variant calling accuracy (greater than 0). Picard (http://sourceforge.net/projects/picard/) was employed to mark duplicates resulted from PCR amplification. GATK IndelRealigner and GATK RealignerTargetCreator were performed to do realignment around the Indels. GATK BaseRecalibrator was performed to do base quality score recalibration. GATK Variant Filtration was performed to make the raw callsets suitable for meaningful analysis. ExomeCNV was performed to do copy number variation (CNV) detection. SAMtools was performed to do variant calling and identify single nucleotide polymorphisms (SNPs) or Indels. After the analysis-ready BAM alignment result was obtained, ANNOVAR (Annotate Variation) was performed to annotate SNPs and Indels. All candidate mutations were filtered against the Single Nucleotide Polymorphism database (dbSNP137, http://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi), 1000 genomes project (2012 April release, http://www. 1000genomes.org/), and NHLBI Exome Sequencing Project (ESP) 6500 to remove the polymorphism loci. Sorting Intolerant from Tolerant (SIFT) and Polymorphism Phenotyping version 2 (PolyPhen-2) were performed to predict whether an amino acid substitution affects function of the protein. Sanger sequencing was employed to validate the identified potential disease-causing variant in family members and 200 normal controls. Sequences of the primers were as follows: 5′-
Results
The clinical data of the three patients from the family are shown in Table 1 . The individuals (IV-1, IV-2, and V-2) presented with no abnormality of muscle or heart. We generated a total of 45.59 million reads of 100-bp paired-end read sequence from the patient V-3, with 45.56 million reads (99.92 %) aligned to the human reference sequence. 50.26 Mb mapped to the targeted region, and 67.42 Mb mapped to the flanking region. About 124.4× sequence depth provided sufficient data to obtain 99.70 % coverage of target exome region. 38,647 genetic variants were identified in either the coding regions or the splice sites. A prioritization scheme was applied to identify the pathogenic mutation in the patient, similar to recent studies [14, 15] . We excluded known variants identified in dbSNP137, 1000 genome project, and NHLBI ESP6500. In addition, we excluded synonymous mutations and predicted function of the mutations by SIFT and PolyPhen-2. Applying the above strategy, we reduced the number of candidate genes by more than 99.44 %. Only a novel homozygous variant (c.107788T>C, p.W35930R) in the TTN gene, a known LGMD2J gene, was identified in 61 candidate homozygous variants which predicted to affect the function of the protein. The homozygous variant completely co-segregated with the LGMD2 phenotype within the family based on further Sanger sequencing, and heterozygous variant were identified in three unaffected family members (IV-1, IV-2, and V-2) (Fig. 1) . MutationTaster predicted that the alteration was disease causing, with a probability value of 0.9998. Additionally, this variant was absent in 700 controls, including 200 normal controls and 500 pathogenic Chinese controls without LGMD from exome sequencing from Novogene. Our data support that it is a pathogenic mutation.
Discussion
In our study, we identified a novel homozygous mutation c.107788T>C (p.W35930R) in the TTN gene in the affected individuals from a consanguineous Chinese Han family with LGMD2J. Mutations in the TTN gene have been identified to be responsible for several phenotypes of skeletal muscle diseases, including tibial muscular dystrophy (TMD, MIM 600334, Udd myopathy) [16] , LGMD2J (MIM 608807) [16] , dilated cardiomyopathy 1G (MIM 604145) [17] , familial hypertrophic cardiomyopathy 9 (MIM 613765) [18] , earlyonset myopathy with fatal cardiomyopathy (MIM 611705) [19] , and proximal myopathy with early respiratory muscle involvement (MIM 603689) [20] . Up to now, about 92 mutations have been described in literature, including missense, splicing, small deletion, and small insertion.
LGMD2J is a severe childhood onset disease-causing proximal muscle weakness in the first or second decade and progresses over the next 20 years to wheelchair confinement [21, 22] . In our study, three individuals (V-1, V-3, and V-4) with the homozygous mutation were normal in childhood and progressive muscle weakness in the lower extremities occurred during the teenage years. They presented with exercise intolerance, frequent fallings, and difficulty in running and climbing stairs, with normal cardiac function. After thirties, none of them were able to walk or raise arms above shoulders (Table 1 ). The heterozygous carriers (IV-1, IV-2, and V-2) presented with no abnormality of muscle or heart.
As a giant sarcomeric protein, the titin spans halfsarcomere from the sarcomeric Z-disc to the M-band and forms a continuous filament system in the myofibrils of striated muscle [23] [24] [25] . Titin is expressed in many different splicing variants, and the molecular weights of numerous muscle-specific variants vary ranging from 3.0 to 3.7 MDa in different skeletal muscles [26, 27] . Most of the alternative splicing events occur in the I-band region, and they may also affect the Z-disc and the M-band region of titin [28] . I-band titin has longer isoforms in skeletal muscle than those in cardiac muscle, but the Z-disc region has longer isoforms in the cardiac muscle [22] . The different titin isoforms may be associated with the selective involvement in anatomically restricted myopathies [29] . The M-band of titin at its extreme C-terminus is a hotspot mutation region [30] .
As a molecular ruler for the myosin-based thick filament and the actin-based thin filament, the titin filament takes part in assembly of sarcomere, the smallest contractile unit of striated muscle cells [22, 26] . The titin may sense the mechanical status of the sarcomere by multiple regulatory sensors and convey information for signaling pathways regulating muscle function, including accounting for passive tension of myofibrils, providing myofibrils with elasticity, distributing forces across sarcomeres, and maintaining the sarcomeric structure during muscle contraction [22, [31] [32] [33] . The titin provides multiple ligand binding sites for a large number of other muscle proteins, including calpain 3, α-actinin, myosin, myomesin, telethonin, and telethonin/T-cap [16] . Mutants of calpain 3, myosin, telethonin, and myotilin are known to cause other muscular dystrophies [34] [35] [36] [37] . Combining with the highly variable expression, the mutant titin proteins result in large variation of phenotypes.
In summary, we have identified a novel mutation, c.107788T>C (p.W35930R), in the TTN gene in a family with LGMD2J. The findings extend our current knowledge of the mutation spectrum of the TTN gene associated with LGMD2J. The identification of these dystrophies through genetic testing will not only inform long-term prognosis but will also assist in directing patient care more efficiently, including more frequent cardiorespiratory monitoring and prophylactic treatments. Nevertheless, further studies are warranted to understand the pathogenesis of dystrophies by detecting titin-associated downstream and upstream signaling pathways that maintain and modify sarcomeric structure and function under stress conditions. 
